We are live on ! Find out more
FCMV

Foresite Capital Management VI Portfolio holdings

AUM $643M
1-Year Est. Return 343.43%
This Fund
S&P 500
This Quarter Est. Return
+21.58%
1 Year Est. Return
+343.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$643M
AUM Growth
+$182M
Cap. Flow
+$95.6M
Cap. Flow %
14.88%
Top 10 Hldgs %
81.55%
Holding
25
New
8
Increased
6
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SPTX
Seaport Therapeutics
SPTX
+$31.3M
2
PBLS
Parabilis Medicines Inc
PBLS
+$27.6M
3
CLDX icon
Celldex Therapeutics
CLDX
+$18.2M
4
GHRS icon
GH Research
GHRS
+$13M
5
JBIO
Jade Biosciences
JBIO
+$11.8M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$54.2M
2
OKUR
OnKure Therapeutics
OKUR
+$5.99M
3
NERV icon
Minerva Neurosciences
NERV
+$5.51K

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
2 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.41B
$168M 26.2%
2,369,574
+148,100
+7% +$9.68M
ALMS
2
Alumis Inc
ALMS
$1.19B
$120M 18.6%
4,247,670
– –
SPTX
3
Seaport Therapeutics
SPTX
$1.25B
$38.7M 6.02%
+1,779,521
New +$31.3M
DNLI icon
4
Denali Therapeutics
DNLI
$3.37B
$35.9M 5.59%
1,396,771
+186,800
+15% +$3.84M
CLDX icon
5
Celldex Therapeutics
CLDX
$2.9B
$32.7M 5.09%
879,713
+563,800
+178% +$18.2M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.01B
$29.1M 4.53%
785,000
+260,000
+50% +$7.89M
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$1.09B
$27.4M 4.26%
1,831,233
– –
PBLS
8
Parabilis Medicines Inc
PBLS
$4.56B
$27.3M 4.26%
+999,044
New +$27.6M
GHRS icon
9
GH Research
GHRS
$1.87B
$25.3M 3.93%
940,493
+625,001
+198% +$13M
JBIO
10
Jade Biosciences
JBIO
$1.14B
$19.7M 3.07%
886,667
+566,667
+177% +$11.8M
HNGE
11
Hinge Health
HNGE
$7.15B
$18.3M 2.85%
220,400
– –
KYMR icon
12
Kymera Therapeutics
KYMR
$9.56B
$16.8M 2.61%
146,332
– –
ATAI icon
13
AtaiBeckley Inc
ATAI
$14.5M 2.26%
2,750,000
– –
VSTM icon
14
Verastem
VSTM
$663M
$12M 1.87%
3,146,631
– –
BEAM icon
15
Beam Therapeutics
BEAM
$2.48B
$11.3M 1.76%
+330,000
New +$9.96M
NERV icon
16
Minerva Neurosciences
NERV
$198M
$11M 1.72%
1,985,584
-1,016
-0.1% -$5.51K
AVBP icon
17
ArriVent BioPharma
AVBP
$1.43B
$10.5M 1.63%
+301,341
New +$8.89M
AURA icon
18
Aura Biosciences
AURA
$726M
$9.47M 1.47%
+1,333,334
New +$9.54M
CRNX
19
DELISTED
Crinetics Pharmaceuticals
CRNX
$7.93M 1.23%
212,010
– –
RACC
20
Research Alliance Corp III
RACC
$103M
$3.21M 0.5%
+300,000
New +$3.13M
ZURA icon
21
Zura Bio
ZURA
$499M
$2.65M 0.41%
450,000
– –
KLRA
22
Kailera Therapeutics
KLRA
$1.81B
$826K 0.13%
+37,500
New +$824K
IRON icon
23
Disc Medicine
IRON
$2.69B
$70.9K 0.01%
+970
New +$66.7K
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,364,019
Closed -$54.2M
OKUR
25
OnKure Therapeutics
OKUR
$126M
– –
-1,445,783
Closed -$5.99M

Similar funds

HP
Holistic Planning Nacogdoches, Texas $643M AUM 18.84% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
GG
GenWealth Group Maplewood, New Jersey $642M AUM 20.77% 1-Year Est. Return
PG
Patten Group Chattanooga, Tennessee $643M AUM 30.24% 1-Year Est. Return
PJSIMP
P.J. Schmidt Investment Management (PJS) Cedarburg, Wisconsin $643M AUM 21.84% 1-Year Est. Return
HA
Harfst & Associates Sheridan, Wyoming $643M AUM 24.12% 1-Year Est. Return
ML
Mayport LLC Newton, Massachusetts $645M AUM 19.45% 1-Year Est. Return
MC
Martin & Co Knoxville, Tennessee $640M AUM 23.57% 1-Year Est. Return

Foresite Capital Management VI's Q2 2026 Portfolio in Review

As of Q2 2026, Foresite Capital Management VI held 25 positions worth $643M, up 40% from $460M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management VI deployed $95.6M of net new capital in Q2 2026, opening 8 new positions and adding to 6 existing holdings. Its largest new stake was Seaport Therapeutics: 1,779,521 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Minerva Neurosciences, an estimated $5.51K trimmed.

  • Foresite Capital Management VI's largest Q2 2026 buy was Seaport Therapeutics: 1,779,521 shares worth $38.7M.
  • Foresite Capital Management VI added most to Celldex Therapeutics in Q2 2026, an estimated $18.2M increase.
  • Foresite Capital Management VI's biggest Q2 2026 reduction was Minerva Neurosciences, cutting an estimated $5.51K.
  • Foresite Capital Management VI fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $54.2M.
  • Foresite Capital Management VI's ten largest holdings make up 82% of its $643M portfolio in Q2 2026.
  • Foresite Capital Management VI opened 8 new positions and closed 2 in Q2 2026.
  • Foresite Capital Management VI's portfolio value rose 40% quarter-over-quarter to $643M.

Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.